CA2271381A1 - Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid - Google Patents

Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid Download PDF

Info

Publication number
CA2271381A1
CA2271381A1 CA002271381A CA2271381A CA2271381A1 CA 2271381 A1 CA2271381 A1 CA 2271381A1 CA 002271381 A CA002271381 A CA 002271381A CA 2271381 A CA2271381 A CA 2271381A CA 2271381 A1 CA2271381 A1 CA 2271381A1
Authority
CA
Canada
Prior art keywords
bismuth
milligrams
composition
days
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271381A
Other languages
English (en)
French (fr)
Inventor
Owen Rickford Carryl
Jonathan Davidson Kaunitz
Shin Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2271381A1 publication Critical patent/CA2271381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002271381A 1996-11-22 1997-11-21 Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid Abandoned CA2271381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75551796A 1996-11-22 1996-11-22
US08/755,517 1996-11-22
PCT/US1997/021462 WO1998022118A1 (en) 1996-11-22 1997-11-21 Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid

Publications (1)

Publication Number Publication Date
CA2271381A1 true CA2271381A1 (en) 1998-05-28

Family

ID=25039481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271381A Abandoned CA2271381A1 (en) 1996-11-22 1997-11-21 Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid

Country Status (7)

Country Link
EP (1) EP0941102A1 (hu)
CN (1) CN1238694A (hu)
CA (1) CA2271381A1 (hu)
HU (1) HUP9904073A3 (hu)
NO (1) NO992468L (hu)
TR (1) TR199901101T2 (hu)
WO (1) WO1998022118A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
EP1154771A4 (en) * 1999-02-26 2005-04-20 Nitromed Inc INHIBITORS OF THE PROTON NITROSIS AND NITROSYL PUMP, COMPOSITIONS AND METHODS OF USE
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
KR100887912B1 (ko) * 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6514960B1 (en) * 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
CA2493618A1 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
EP2262790B1 (en) 2008-03-10 2017-06-07 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2023143573A1 (zh) * 2022-01-30 2023-08-03 上海石趣医药科技有限公司 含铋化合物在用于治疗疾病中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
EP0681476B1 (en) * 1991-11-22 1997-08-27 The Procter & Gamble Company Unit dose form of bismuth subsalicylate
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.

Also Published As

Publication number Publication date
WO1998022118A1 (en) 1998-05-28
HUP9904073A3 (en) 2000-04-28
NO992468D0 (no) 1999-05-21
TR199901101T2 (xx) 1999-07-21
HUP9904073A2 (hu) 2000-03-28
EP0941102A1 (en) 1999-09-15
NO992468L (no) 1999-07-01
CN1238694A (zh) 1999-12-15

Similar Documents

Publication Publication Date Title
CA2271381A1 (en) Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
EP0941101A1 (en) Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
JP2648327B2 (ja) 胃腸疾患を治療するための組成物及び方法
Reimer Safety of long-term PPI therapy
Levi et al. Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism.
JP6366548B2 (ja) 胃酸分泌の即効性阻害剤
Lane et al. Recurrence of duodenal ulcer after medical treatment
Chey et al. Lansoprazole and Ranitidine Affect the Accuracy of the 14 C-Urea Breath Test by a pH-Dependent Mechanism.
EP0206626B1 (en) Use of bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by campylobacter polyridis
JPS6248623A (ja) 胃腸疾患の治療のための医薬組成物
Salmon et al. Evaluation of colloidal bismuth (De-Nol) in the treatment of duodenal ulcer employing endoscopic selection and follow up
Bough Jr et al. Gastroesophageal reflux laryngitis resistant to omeprazole therapy
Vergara et al. Helicobacter pylorieradication prevents recurrence from peptic ulcer haemorrhage
Marks, IN & Girdwood Recurrence of duodenal ulceration in patients on maintenance sucralfate-a 12-month follow-up study
Akase et al. A comparative study of laboratory parameters and symptoms effected by Toki-shakuyaku-san and an iron preparation in rats with iron-deficiency anemia
Treiber et al. Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function
Fraser et al. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
CA2122478C (en) Unit dose form of bismuth subsalicylate
KR20100124054A (ko) 더덕 추출물 또는 더덕 사포닌을 포함하는 히스타민 분비 억제용 조성물
Merki et al. Treatment with H2-receptor antagonists: when is the best time to dose?
George et al. Peptic ulcer disease in children
CASTLES et al. Peptic ulcer and gastrin in pigs
Gustavsson et al. Future strategies in acid-peptic disorders: concluding remarks
SATO et al. The effects of a prostaglandin E1 analogue, misoprostol, on gastric mucosal blood volume index and haemoglobin oxygenation in humans
Britt Pedunculated islet-cell tumour of the duodenum

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued